Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Number of Participants With Malignant Alteration of Epithelial Cells |
Numbers of participants with malignant alteration of epithelial cells for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. |
Time Frame: Up to Week 268 (Week 260 in Maintenance Phase) |
|
Primary |
Number of Participants With Parietal Cell Protrusion/Hyperplasia |
Numbers of participants with parietal cell protrusion/hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Primary |
Number of Participants With Foveolar Hyperplasia |
Numbers of participants with foveolar hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Primary |
Number of Participants With Enterochromaffin-like-cell Hyperplasia |
Numbers of participants with enterochromaffin-like-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Primary |
Number of Participants With G-cell Hyperplasia |
Numbers of participants with G-cell hyperplasia for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for gastric mucosa histopathology. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Percentage of Participants With Recurrence of Erosive Esophagitis (EE) |
Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades O and A to D) during the Maintenance Phase. The LA classification graded as follows- Grade O: normal mucosa; Grade A: nonconfluent mucosal breaks <5 mm in length; Grade B: nonconfluent mucosal breaks = 5mm in length; Grade C: confluent mucosal breaks <75% circumferential; Grade D: confluent mucosal breaks >75% circumferential. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Percentage of Participants Who Healed EE at the End of Healing Phase |
Percentage of participants who healed EE at the end of healing phase was reported. |
Up to Week 8 |
|
Secondary |
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) in Maintenance Phase |
Number of participants reporting one or more TEAEs in Maintenance Phase was reported. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. |
260 weeks (Baseline, up to the end of Maintenance Phase) |
|
Secondary |
Number of Participants With Fundic Gland Polyp |
Numbers of participants with fundic gland polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Hyperplastic Polyp |
Numbers of participants with hyperplastic polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Cobblestone Mucosa |
Numbers of participants with cobblestone mucosa for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Multiple White and Flat Elevated Lesions |
Numbers of participants with multiple white and flat elevated lesions for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Black Spots |
Numbers of participants with black spots for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as the endpoint for endoscopic findings. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Middle Gastric Body |
Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Inflammation (Mononuclear Infiltration) in Greater Curvature of Antrum |
Numbers of participants with inflammation (mononuclear infiltration) in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Middle Gastric Body |
Numbers of participants with neutrophilic infiltration in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Neutrophilic Infiltration in Greater Curvature of Antrum |
Numbers of participants with neutrophilic infiltration in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Atrophy in Greater Curvature of Middle Gastric Body |
Numbers of participants with atrophy in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Atrophy in Greater Curvature of Antrum |
Numbers of participants with atrophy in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Intestinal Metaplasia in Greater Curvature of Middle Gastric Body |
Numbers of participants with intestinal metaplasia in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Intestinal Metaplasia in Greater Curvature of Antrum |
Numbers of participants with intestinal metaplasia in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Presence of H.Pylori in Greater Curvature of Middle Gastric Body |
Numbers of participants with presence of H.pylori in greater curvature of the middle gastric body for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Presence of H.Pylori in Greater Curvature of Antrum |
Numbers of participants with presence of H.pylori in greater curvature of the antrum for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported as histological assessment of gastritis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|
Secondary |
Number of Participants With Gastric Polyp |
Numbers of participants with gastric polyp for Vonoprazan group and Lansoprazole group at Week 268 (Week 260 in Maintenance Phase) were reported. The number analyzed is the number of participants with data available for analysis. |
Up to Week 268 (Week 260 in Maintenance Phase) |
|